SEC Form 4 · accession 0000899243-18-027477

LogicBio Therapeutics, Inc. · LOGC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 23, 2018

Accepted (ET)

Oct 25, 2018 · 6:25 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001664106

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Oct 23, 2018	C	2,279,023	—	A	2,279,023	I	See Footnote
Common Stock^F2	Oct 23, 2018	P	700,000	$10.00	A	2,979,023	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Convertible Preferred Stock^F2,F1	—	Oct 23, 2018	C	4,352,775	D	—	—	Common Stock	2,279,023	0	I

F1Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
F2The Reporting Person is an investment manager of Arix Bioscience, Inc. Arix Bioscience, Inc. and Arix Bioscience Holdings Limited, the direct beneficial owner of these securities, are each wholly owned subsidiaries of Arix Bioscience plc. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.